Mitral regurgitation treatment overview: Difference between revisions
Gerald Chi (talk | contribs) No edit summary |
|||
(8 intermediate revisions by 6 users not shown) | |||
Line 1: | Line 1: | ||
{ | __NOTOC__ | ||
{| class="infobox" style="float:right;" | |||
|- | |||
| [[File:Siren.gif|30px|link=Mitral regurgitation resident survival guide]]|| <br> || <br> | |||
| [[Mitral regurgitation resident survival guide|'''Resident'''<br>'''Survival'''<br>'''Guide''']] | |||
|} | |||
{| class="infobox" style="float:right;" | |||
|- | |||
| [[File:Critical_Pathways.gif|88px|link=Mitral regurgitation critical pathways]]|| <br> || <br> | |||
|} | |||
{{Mitral regurgitation}} | |||
{{CMG}}; {{AE}} {{CZ}}; [[Varun Kumar]], M.B.B.S ; [[Lakshmi Gopalakrishnan]], M.B.B.S | |||
==Overview== | ==Overview== | ||
Vasodilator therapy with [[ACE inhibitors]] and [[hydralazine]] is the foundation of medical therapy and once the patient becomes symptomatic, mitral valve surgery is the definitive therapy. This chapter reviews general treatment measures for the patient with mitral regurgitation. | |||
*[[ | ==Afterload Reduction== | ||
* Afterload reduction should be instituted with the use of [[vasodilators]] such as [[ACE inhibitors]] and [[hydralazine]]. | |||
* | ==Diuretics== | ||
*Diuretics are useful in reducing left ventricular volumes to improve functional mitral regurgitation and to improve pulmonary edema. | |||
* | ==Digitalis== | ||
*[[Digitalis]] may be used to strengthen contractility, and potentially reduce hospitalization in patients with congestive heart failure. | |||
* | ==Diet== | ||
*A low-sodium diet may be helpful. | |||
* | ==Activity== | ||
*Most patients with chronic compensated mitral regurgitation have no symptoms; but if a person develops symptoms, activity should be restricted. | |||
==Beta Blockers== | |||
Beta blockers are generally not recommended as they would slow the compensatory tachycardia and would allow greater time over which the regurgitation could occur and increase the regurgitant volume. | |||
==Calcium Channel Blockers== | |||
* In the presence of [[atrial fibrillation]], a [[calcium channel blocker]] or [[digoxin]] can be administered to slow the heart rate down and improve left ventricular filling. | |||
==Cardioversion== | |||
Cardioversion should be considered in the patient with atrial fibrillation or flutter who is hemodynamically unstable. | |||
==Anticoagulation== | |||
* Anti-coagulation therapy should be considered in patients with [[atrial fibrillation]] and in patients with prosthetic [[mitral valve replacement]] surgery. | * Anti-coagulation therapy should be considered in patients with [[atrial fibrillation]] and in patients with prosthetic [[mitral valve replacement]] surgery. | ||
==Antibiotic Prophylaxis== | |||
* Prophylactic antibiotics prior to a periodontal procedure which involves manipulation of gingival tissue, the periapical region of a tooth, or perforation of oral mucosa is recommended in patients with previous infective endocarditis, patients who have a prosthetic mitral valve implanted and in those with congentital heart disease.<ref name="pmid17446442">{{cite journal |author=Wilson W, Taubert KA, Gewitz M, Lockhart PB, Baddour LM, Levison M, Bolger A, Cabell CH, Takahashi M, Baltimore RS, Newburger JW, Strom BL, Tani LY, Gerber M, Bonow RO, Pallasch T, Shulman ST, Rowley AH, Burns JC, Ferrieri P, Gardner T, Goff D, Durack DT |title=Prevention of infective endocarditis: guidelines from the American Heart Association: a guideline from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group |journal=[[Circulation]] |volume=116 |issue=15 |pages=1736–54 |year=2007 |month=October |pmid=17446442 |doi=10.1161/CIRCULATIONAHA.106.183095 |url=http://circ.ahajournals.org/cgi/pmidlookup?view=long&pmid=17446442 |accessdate=2011-03-16}}</ref> | * Prophylactic antibiotics prior to a periodontal procedure which involves manipulation of gingival tissue, the periapical region of a tooth, or perforation of oral mucosa is recommended in patients with previous infective endocarditis, patients who have a prosthetic mitral valve implanted and in those with congentital heart disease.<ref name="pmid17446442">{{cite journal |author=Wilson W, Taubert KA, Gewitz M, Lockhart PB, Baddour LM, Levison M, Bolger A, Cabell CH, Takahashi M, Baltimore RS, Newburger JW, Strom BL, Tani LY, Gerber M, Bonow RO, Pallasch T, Shulman ST, Rowley AH, Burns JC, Ferrieri P, Gardner T, Goff D, Durack DT |title=Prevention of infective endocarditis: guidelines from the American Heart Association: a guideline from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group |journal=[[Circulation]] |volume=116 |issue=15 |pages=1736–54 |year=2007 |month=October |pmid=17446442 |doi=10.1161/CIRCULATIONAHA.106.183095 |url=http://circ.ahajournals.org/cgi/pmidlookup?view=long&pmid=17446442 |accessdate=2011-03-16}}</ref> | ||
==References== | ==References== | ||
Line 25: | Line 50: | ||
[[Category:Valvular heart disease]] | [[Category:Valvular heart disease]] | ||
[[Category:Cardiology]] | [[Category:Cardiology]] | ||
[[Category:Disease]] | |||
[[Category:Cardiac surgery]] | |||
[[Category:Surgery]] | [[Category:Surgery]] | ||
[[Category:Overview complete]] | [[Category:Overview complete]] | ||
{{WikiDoc Help Menu}} | {{WikiDoc Help Menu}} | ||
{{WikiDoc Sources}} | {{WikiDoc Sources}} |
Latest revision as of 23:29, 18 August 2013
Resident Survival Guide |
File:Critical Pathways.gif |
Mitral Regurgitation Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Mitral regurgitation treatment overview On the Web |
American Roentgen Ray Society Images of Mitral regurgitation treatment overview |
Risk calculators and risk factors for Mitral regurgitation treatment overview |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Cafer Zorkun, M.D., Ph.D. [2]; Varun Kumar, M.B.B.S ; Lakshmi Gopalakrishnan, M.B.B.S
Overview
Vasodilator therapy with ACE inhibitors and hydralazine is the foundation of medical therapy and once the patient becomes symptomatic, mitral valve surgery is the definitive therapy. This chapter reviews general treatment measures for the patient with mitral regurgitation.
Afterload Reduction
- Afterload reduction should be instituted with the use of vasodilators such as ACE inhibitors and hydralazine.
Diuretics
- Diuretics are useful in reducing left ventricular volumes to improve functional mitral regurgitation and to improve pulmonary edema.
Digitalis
- Digitalis may be used to strengthen contractility, and potentially reduce hospitalization in patients with congestive heart failure.
Diet
- A low-sodium diet may be helpful.
Activity
- Most patients with chronic compensated mitral regurgitation have no symptoms; but if a person develops symptoms, activity should be restricted.
Beta Blockers
Beta blockers are generally not recommended as they would slow the compensatory tachycardia and would allow greater time over which the regurgitation could occur and increase the regurgitant volume.
Calcium Channel Blockers
- In the presence of atrial fibrillation, a calcium channel blocker or digoxin can be administered to slow the heart rate down and improve left ventricular filling.
Cardioversion
Cardioversion should be considered in the patient with atrial fibrillation or flutter who is hemodynamically unstable.
Anticoagulation
- Anti-coagulation therapy should be considered in patients with atrial fibrillation and in patients with prosthetic mitral valve replacement surgery.
Antibiotic Prophylaxis
- Prophylactic antibiotics prior to a periodontal procedure which involves manipulation of gingival tissue, the periapical region of a tooth, or perforation of oral mucosa is recommended in patients with previous infective endocarditis, patients who have a prosthetic mitral valve implanted and in those with congentital heart disease.[1]
References
- ↑ Wilson W, Taubert KA, Gewitz M, Lockhart PB, Baddour LM, Levison M, Bolger A, Cabell CH, Takahashi M, Baltimore RS, Newburger JW, Strom BL, Tani LY, Gerber M, Bonow RO, Pallasch T, Shulman ST, Rowley AH, Burns JC, Ferrieri P, Gardner T, Goff D, Durack DT (2007). "Prevention of infective endocarditis: guidelines from the American Heart Association: a guideline from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group". Circulation. 116 (15): 1736–54. doi:10.1161/CIRCULATIONAHA.106.183095. PMID 17446442. Retrieved 2011-03-16. Unknown parameter
|month=
ignored (help)